263 related articles for article (PubMed ID: 33982878)
21. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.
Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA
Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559
[TBL] [Abstract][Full Text] [Related]
22. Wild-type p53-induced phosphatase 1 down-regulation promotes apoptosis by activating the DNA damage-response pathway in amyotrophic lateral sclerosis.
Yang YQ; Zheng YH; Zhang CT; Liang WW; Wang SY; Wang XD; Wang Y; Wang TH; Jiang HQ; Feng HL
Neurobiol Dis; 2020 Feb; 134():104648. PubMed ID: 31676238
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of wild-type p53-induced phosphatase 1 (Wip1) plays a critical role in regulating several p53-dependent functions in premature senescent tumor cells.
Crescenzi E; Raia Z; Pacifico F; Mellone S; Moscato F; Palumbo G; Leonardi A
J Biol Chem; 2013 Jun; 288(23):16212-16224. PubMed ID: 23612976
[TBL] [Abstract][Full Text] [Related]
24. Expression of a homeostatic regulator, Wip1 (wild-type p53-induced phosphatase), is temporally induced by c-Jun and p53 in response to UV irradiation.
Song JY; Han HS; Sabapathy K; Lee BM; Yu E; Choi J
J Biol Chem; 2010 Mar; 285(12):9067-76. PubMed ID: 20093361
[TBL] [Abstract][Full Text] [Related]
25. Wip1 phosphatase-deficient mice exhibit defective T cell maturation due to sustained p53 activation.
Schito ML; Demidov ON; Saito S; Ashwell JD; Appella E
J Immunol; 2006 Apr; 176(8):4818-25. PubMed ID: 16585576
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway.
Zhang X; Wan G; Mlotshwa S; Vance V; Berger FG; Chen H; Lu X
Cancer Res; 2010 Sep; 70(18):7176-86. PubMed ID: 20668064
[TBL] [Abstract][Full Text] [Related]
27. WIP1 phosphatase suppresses the DNA damage response during G2/prophase arrest in mouse oocytes.
Leem J; Kim JS; Oh JS
Biol Reprod; 2018 Oct; 99(4):798-805. PubMed ID: 29733326
[TBL] [Abstract][Full Text] [Related]
28. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
[TBL] [Abstract][Full Text] [Related]
29. p53-Independent expression of wild-type p53-induced phosphatase 1 (Wip1) in methylmethane sulfonate-treated cancer cell lines and human tumors.
Park JY; Song JY; Kim HM; Han HS; Seol HS; Jang SJ; Choi J
Int J Biochem Cell Biol; 2012 Jun; 44(6):896-904. PubMed ID: 22405851
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic WIP1 phosphatase attenuates the DNA damage response and sensitizes p53 mutant Jurkat cells to apoptosis.
Eren MK; Kartal NB; Pilevneli H
Oncol Lett; 2021 Jun; 21(6):479. PubMed ID: 33968195
[TBL] [Abstract][Full Text] [Related]
31. WIP1 phosphatase as pharmacological target in cancer therapy.
Pecháčková S; Burdová K; Macurek L
J Mol Med (Berl); 2017 Jun; 95(6):589-599. PubMed ID: 28439615
[TBL] [Abstract][Full Text] [Related]
32. miR-15b/16-2 regulates factors that promote p53 phosphorylation and augments the DNA damage response following radiation in the lung.
Rahman M; Lovat F; Romano G; Calore F; Acunzo M; Bell EH; Nana-Sinkam P
J Biol Chem; 2014 Sep; 289(38):26406-26416. PubMed ID: 25092292
[TBL] [Abstract][Full Text] [Related]
33. Ascochlorin activates p53 in a manner distinct from DNA damaging agents.
Jeong JH; Nakajima H; Magae J; Furukawa C; Taki K; Otsuka K; Tomita M; Lee IS; Kim CH; Chang HW; Min KS; Park KK; Park KK; Chang YC
Int J Cancer; 2009 Jun; 124(12):2797-803. PubMed ID: 19253369
[TBL] [Abstract][Full Text] [Related]
34. Alkyl-substituted N-methylaryl-N'-aryl-4-aminobenzamides: A new series of small molecule inhibitors for Wip1 phosphatase.
Robello M; Zheng H; Saha M; George Rosenker KM; Debnath S; Kumar JP; Tagad HD; Mazur SJ; Appella E; Appella DH
Eur J Med Chem; 2022 Dec; 243():114763. PubMed ID: 36179402
[TBL] [Abstract][Full Text] [Related]
35. WIP1 dephosphorylation of p27
Choi BK; Fujiwara K; Dayaram T; Darlington Y; Dickerson J; Goodell MA; Donehower LA
Cell Cycle; 2020 Feb; 19(4):479-491. PubMed ID: 31959038
[TBL] [Abstract][Full Text] [Related]
36. PP2Cδ inhibits p300-mediated p53 acetylation via ATM/BRCA1 pathway to impede DNA damage response in breast cancer.
Li Q; Hao Q; Cao W; Li J; Wu K; Elshimali Y; Zhu D; Chen QH; Chen G; Pollack JR; Vadgama J; Wu Y
Sci Adv; 2019 Oct; 5(10):eaaw8417. PubMed ID: 31663018
[TBL] [Abstract][Full Text] [Related]
37. ROLE OF Wip1-p53 AXIS IN RESPONSE OF MURINE CELLS TO TREATMENT WITH SODIUM BUTYRATE AND MEK/ERK SIGNALLING PATHWAY INHIBITOR.
Kochetkova EA; Demidov ON
Tsitologiia; 2017; 59(4):285-9. PubMed ID: 30188093
[TBL] [Abstract][Full Text] [Related]
38. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
Spinnler C; Hedström E; Li H; de Lange J; Nikulenkov F; Teunisse AF; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
Cell Death Differ; 2011 Nov; 18(11):1736-45. PubMed ID: 21546907
[TBL] [Abstract][Full Text] [Related]
39. Wild-type p53-induced phosphatase 1 (Wip1) forestalls cellular premature senescence at physiological oxygen levels by regulating DNA damage response signaling during DNA replication.
Sakai H; Fujigaki H; Mazur SJ; Appella E
Cell Cycle; 2014; 13(6):1015-29. PubMed ID: 24552809
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of Wip1 overexpression and its association with the p38MAPK/p53/p16 pathway in NSCLC.
Yang S; Dong S; Qu X; Zhong X; Zhang Q
Mol Med Rep; 2017 Feb; 15(2):719-723. PubMed ID: 27959454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
